On Tuesday, Nolan Langweil (Principal Fiscal Analyst, Joint Fiscal Office)  reviewed S.98 with the House Appropriations Committee. The bill relates to Green Mountain Care Board (GMCB) authority over prescription drug costs. The House Health Care Committee had made amendments concerning the GMCB Nominating Committee, and then passed the bill on to this Committee.

Beth Anderson (President and CEO, Vermont Information Technology Leaders (VITL)) testified at the House Health Care Committee on Friday to review the purpose and activities of the organization. VITL was founded in 2005 and operates the Vermont Health Information Exchange (VHIE). The plan was approved by the Green Mountain Care Board (GMCB). The GMCB has the authority to approve VITL’s budget.

The Health Equity Advisory Commission (HEAC) presented to a joint Committee meeting of the House Health Care and Senate Health and Welfare on Wednesday. The agenda included an overview of the HEAC responsibilities, a summary of the HEAC’s 2023 Annual Report, budget and fiscal proposals, and final notes and reflections. The Commission members include thirty representatives from various entities in Vermont. Rev. Mark Hughes is the Chair and represents Vermont Racial Justice Alliance. He and Kristen Murphy (Executive Director, Vermont Developmental Disabilities Council) presented the annual report to the committee, which included government equity, programmatic approach/framework, community engagement, legal and administrative support, policies and programs, funding, grants and training, and continuing education.

The House Health Care Committee took up H.206, which is entitled “An act relating to miscellaneous changes affecting the duties of the Department of Vermont Health Access,” on Thursday. Stephanie Winters of the Vermont Medical Society (VMS) shared the perspective of the VMS on Section 3 of the bill pertaining to the Vermont Prescription System (VPMS) and the use of the data in this important registry. She reiterated that “VMS was involved in the design of VPMS at its inception and has always been our position that the focus should be clinical improvement and coordination and not enforcement purposes.”